Table 1.

Clinical data, genetics and TART characteristics.

Patient	Age at diagnosis/clinical form	Ultrasound follow-up before TART (years)	Age at Dg of TART (years)	Tanner stage/tumor stage	Genotype allele 1/allele 2	Metabolic control	MRI/histology	TART after tightened control
1a,b	Newborn/SW	4	14.9	4/4	p.Q318X/p.Q318X	Poor	+/+	Larger
2	Newborn/SW	7	12.5	3/3	In2G/In2G	Poor	NA/NA	Smaller
3c	Newborn/SW	4	14	5/5	In2G/In2G	Poor	+/+	Larger
4b	Newborn/SW	7.5	15.3	5/2	In2G/p.Q318X	Poor	+/NA	Smaller
5	9 years/SV	5	11	2/2	p.P30L/p.P30L	Tight	NA/NA	Unchanged
6d	2 years/SV	5	7	1/2	p.I172N/p.I172N	Tight	+/NA	Unchanged
7	Newborn/SW	9	16	5/2	del8bp ex3/del8bp ex3	Tight	+/NA	Smaller
8	9 years/SV	7	10	1/2	In2G/In2G	Poor	NA/NA	Unchanged

^aPatient developed mixed ALL/AML leukemia; ^bpatient has a brother with the same mutation and metabolic control, but no TART; ^cLeydig cell tumor suspected; ^dpreviously unreported genotype.

MRI, magnetic resonance imaging; NA, non-applicable; SV, simple virilizing; SW, salt wasting; TART, testicular adrenal rest tumors.